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Abstract
Background: T-cell activation is an essential step of immune response. The process of proper T-
cell activation is strictly monitored and regulated by apoptosis signaling. Yet, regulation of
apoptosis, an integral and crucial facet during the process of T-cell activation, is not well
understood.
Methods: In this study, a Gene-Ontology driven global gene expression analysis coupled with
protein abundance and activity assays identified genes and pathways associated with regulation of
apoptosis in primary human CD3+ T cells and separately CD4+ and CD8+ T cells.
Results: We identified significantly regulated apoptotic genes in several protein families, such as
BCL2 proteins, CASPASE proteins, and TNF receptors, and detailed their transcriptional kinetics
during the T-cell activation process. Transcriptional patterns of a few select genes (BCL2A1, BBC3
and CASP3) were validated at the protein level. Many of these apoptotic genes are involved in NF-
κB signaling pathway, including TNFRSF10A, TNFRSF10B, TRAF4, TRAF1, TRAF3, and TRAF6.
Upregulation of NF-κB and IκB family genes (REL, RELA, and RELB, NFKBIA, NFKBIE and NFKB1)
at 48 to 96 hours, supported by the increase of phosphorylated RELA (p65), suggests that the
involvement of the NF-κB complex in the process of T-cell proliferation is not only regulated at
the protein level but also at the transcriptional level. Examination of genes involved in MAP kinase
signalling pathway, important in apoptosis, suggests an induction of p38 and ERK1 cascades in T-
cell proliferation (at 48 to 96 hours), which was explored using phosphorylation assays for p38
(MAPK14) and ERK1 (MAPK3). An immediate and short-lived increase of AP-1 activity measured
by DNA-binding activity suggests a rapid and transient activation of p38 and/or JNK cascades upon
T-cell activation.
Conclusion: This comparative genome-scale, transcriptional analysis of T-cell activation in the
CD4+ and CD8+ subsets and the mixed CD3+ population identified many apoptosis genes not
previously identified in the context of T-cell activation. Furthermore, it provided a comprehensive
temporal analysis of the transcriptional program of apoptosis associated with T-cell activation.
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Background
The adaptive immune response starts with the activation
of the naive CD4+ and CD8+ T cells in the peripheral
immune system. Successful T-cell activation requires the
T-cell receptor complex (TCR) and the co-receptor CD28
[1], the ligation of which leads to several downstream sig-
nalling events, including activation of protein kinases
such as LCK and ZAP70, activation of MAP kinase cas-
cades, and activation and nuclear localization of crucial
transcription factors including AP-1, NFAT, and NF-κB
[2]. In contrast, TCR signaling alone without CD28 co-
stimulation results in anergy and eventual cell death [3].
Apoptosis has been extensively examined in T cells post
activation, such as activation-induced cell death (AICD),
due to its essential role in eliminating unwanted lym-
phocytes and maintaining the homeostasis after fighting
infection and inflammation [4]. However, the regulation
of apoptosis and the balance between the anti-apoptotic
and pro-apoptotic signalling (which is an essential part of
the surveillance machinery) during the process of T-cell
activation have not been examined.
Genome-scale transcriptional analysis is a powerful tool
for understanding complex processes such as T-cell activa-
tion [5,6]. In a previous effort, using ontological analysis
coupled with a comparative analysis of primary human T-
cell activation in the CD3+ T cells and the two subsets,
CD4+ and CD8+ T cells, we probed the common and
potentially subset-specific immune response-associated
transcriptome in T-cell activation [7]. In this study we
focus on the differentially expressed genes associated with
regulation of apoptosis, as well as essential apoptotic sig-
nalling pathways: the NF-κB signalling pathway, and MAP
kinase signalling. We identified several potentially impor-
tant apoptotic genes based on their patterns of expression
and examined the protein expression of a select set of
genes, most of which have not been previously discussed
in T-cell activation.
Methods
Cells and culture system
CD3+, CD4+ and CD8+ T-cell cultures were set up as pre-
viously described [7]. Briefly, negatively-selected T cells
(CD3+, CD4+, and CD8+) were activated with anti-CD3/
anti-CD28 Mab conjugated to magnetic beads. Cell count-
ing and sampling for flow cytometry and microarray anal-
ysis were carried out at 0, 4, 10, 48 and 96 hours in the
CD3+ T-cell experiments, E1-E5, with cells from 5 inde-
pendent healthy donors, and at 0, 6, 12, 24, 48 and 72
hours in the CD4+ T-cell and CD8+ T-cell experiments,
E7-E11, with cells from 5 independent healthy donors.
This study was approved by the Northwestern University
IRB.
Flow cytometry
The following monoclonal antibodies (Mabs) for flow
cytometry were purchased from BD Biosciences (San Jose,
CA) unless otherwise stated and included CD3
(FITC+PE), active CASP3 PE, phospho-NF-κB-p65 PE,
phospho-p38 (MAPK14) PE, phospho-ERK1 (MAPK3)
PE, PUMA (BBC3) (Cell Signaling Technology, Danvers,
MA), BCL2A1 (Abcam, Cambridge, MA) and goat anti
rabbit IgG PE (Jackson ImmunoResearch Laboratories,
West Grove, PA). Flow cytometry was carried out as
described[8,9]. Briefly, all samples were gated on forward
scatter and on propidium iodide negative (PI-) to elimi-
nate debris and dead cells. For intracellular detections,
cells were first stained with anti-CD3-FITC and then fixed,
permeabilized, and stained as previously described [10].
Quantibrite beads (BD Biosciences Immunocytometry
Systems) labelled with different amounts of PE molecules
were used to quantify surface or intracellular protein lev-
els and normalize measurements between timepoints.
Microarray experiments and data analysis
Total RNA was extracted, RNA integrity was evaluated and
microarray experiments and data analysis were carried out
as previously described [7]. Briefly, microarray data were
normalized and further analyzed (identification of signif-
icant genes, hierarchical clustering, and Gene Ontology
assignment) with 'MultiExperiment Viewer (MeV)' from
The Institute for Genomic Research (TIGR) [11]. Raw and
normalized data were deposited in the Gene Expression
Omnibus (GSE6607 (CD3+ T-cell experiment), GSE7571
(CD4+ T-cell experiment) and GSE7572 (CD8+ T-cell
experiment)) [12]. Within each population (three biolog-
ical replicates using cells from three different donors),
multi-class SAM (Significance Analysis of Microarrays)
with a false discovery rate of < 1% was used to select genes
that show statistically different expression between
groups. A SAM group is defined here as all the samples
belonging to the same timepoint regardless of donor.
Briefly, there were 5 groups (0 hour, 4, 10, 48 and 96
hours) in the set of CD3+ experiments and 6 groups (0
hour, 6, 12, 24, 48 and 72 hours) in the set of CD4+ exper-
iments and CD8+ experiments. Gene expression at each
time point was compared to that of 0 hour in each exper-
iment. Gene Ontology annotations, as curated by Euro-
pean Bioinformatics Institute, were retrieved from the
Gene Ontology Consortium website [13]. The EASE
(Expression Analysis Systematic Explorer) score in onto-
logical analysis is a modified Fisher Exact Probability p-
value [14] indicating the probability of finding by chance
the same degree of enrichment on a Gene Ontology term
in a set of genes. The lower the EASE score, the more sig-
nificant is the enrichment, i.e. the less likely that degree of
enrichment can be found by chance. Hierarchical cluster-
ing analysis was performed with the Euclidean distance
metric. The list of genes associated with NF-κB signalingBMC Medical Genomics 2008, 1:53 http://www.biomedcentral.com/1755-8794/1/53
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pathway was curated based on the information of Gene
Ontology Consortium [13] per 'positive regulation of I-
kappaB kinase/NF-kappaB cascade' and superarray [15]
per 'NF-κB Signalling Pathway'. Information of superarray
enriched our list with members of the Rel, NF-κB, and IκB
families. The list of NF-κB target genes was curated based
on the information of website ([16]), a collective informa-
tion source of NF-κB research based on updated publica-
tions. The gene list of MAP kinase signalling pathway was
curated and sorted based on information of Kegg website
[17] per 'MAPK signalling pathway', superarray [15] per
'MAP Kinase Signalling Pathway', and NCBI website [18].
AP-1 activity assay
DNA-binding activity of AP-1 was assessed using the
TransBinding AP-1 ELISA kit (Panomics; Fremont, CA) as
described [19]. Briefly, nuclear extracts were incubated
with biotinylated AP-1-consensus-binding-sequence oli-
gonucleotides and complexes were detected using a pri-
mary AP-1 antibody and a secondary antibody conjugated
to horseradish peroxidase. This assay is analogous to the
traditional electrophoretic mobility shift assay in that it
measures the ability of a transcription factor from nuclear
lysates to bind to a consensus-binding sequence of that
transcription factor, and has been extensively validated
[20,21].
Results
Anti- and pro-apoptotic genes in T-cell activation
As previously reported, within each population (CD3+,
CD4+ and CD8+ T cells), T cells from three independent
biological donors (three biological replicates) exhibited
overall similar phenotypic characteristics [7]. Briefly, the
surface expression of the early T-cell activation marker
CD69 and the middle activation marker CD25 (IL2RA)
[22] were rapidly upregulated within 10 hours and 24
hours respectively; T-cell proliferation did not start until
48 hours and cell numbers doubled by 96 hours following
T-cell activation. Accordingly, we divided our experimen-
tal time course into early T-cell activation (0–10 hours),
middle and late T-cell activation (10–48 hours), and T-
cell proliferation (48–96 hours). Our microarray results
have been validated by Q-RT-PCR assays with a selection
of fifteen significant genes covering a broad range of
expression patterns and intensities [7]. We have also
established the reproducibility of our genome scale tran-
scription data within each population (CD3+, CD4+ and
CD8+ T cells) and across the three populations [7]. SAM
analysis identified a total of 4167 unique, significant reg-
ulated genes in T-cell activation, with similar transcription
patterns in three replicate biological experiments within
each population [7].
Following SAM analysis, ontological analysis using the
MeV EASE module identified 125 significantly regulated
genes, associated with 'regulation of apoptosis' (EASE
score: 7.65E-08), which shows that there is an active
involvement of the apoptotic machinery during T-cell
activation and proliferation. Made up of both anti- and
pro-apoptotic genes, these 125 genes shared well-pre-
served expression patterns among the three T-cell popula-
tions (Figure 1A and Figure 1B). The mainly upregulated
cluster (Figure 1A) contains both anti- and pro-apoptotic
genes, and so does the mainly downregulated cluster (Fig-
ure 1B). This suggests an essential role of the balance
between anti- apoptotic and pro- apoptotic signalling in
T-cell activation.
Members of the BCL2 family are key regulators of apopto-
sis. The balance between pro- and anti-apoptotic BCL2
family members determines the cellular fate in response
to survival cues and stress signals [23]. The functions and
transcriptional regulation of these BCL2 family genes in T-
cell activation remain largely unexplored. Alves et al.
reported several significantly regulated BCL2 family genes
in T-cell activation without discussion [24]. Our microar-
ray data identified a set of significantly regulated BCL2
family genes reported by Alves [24], but with different
transcriptional patterns (Figure 1). These included contin-
uously upregulated BCL2A1 (anti-apoptotic), early upreg-
ulated MCL1 (myeloid cell leukemia sequence 1) (anti-
apoptotic), BMF (BCL2 modifying factor) (pro-apoptotic)
and PMAIP1 (pro-apoptotic), late (48 hours) downregu-
lated BCL2 and dynamically (up-down-up) regulated
BBC3 (pro-apoptotic). Flow cytometric assays (sample
flow cytometry histograms shown in Additional file 2
.)demonstrated the continuous upregulation of BCL2A1
(Figure 2A) and upregulation of BBC3 at 0–10 hours and
24–96 hours at the protein level (Figure 2C), both of
which are consistent with their transcriptional patterns.
The BCL2A1 gene has been reported as a direct target of
transcription factor NF-κB complex, p65/p50, in T cells
[25]. This indicates a continuous involvement of BCL2A1
and a constant activity of the NF-κB (p65/p50) complex
in T-cell activation. BCL2 has been hypothesized to be
able to block T-cell death [26]. The significant regulation
of several genes of the BCL2 protein family and their inter-
acting proteins, whose functions and transcription regula-
tion have not been discussed in the context of T-cell
activation, calls for attention to their role in T-cell activa-
tion. These include upregulated early (anti-apoptotic
BNIP2 (BCL2/adenovirus interacting protein 2)), at 10–
48 hours (anti-apoptotic BAG1 (BCL2-associated athano-
gene)), and late BAG2, BCL2L12, and pro-apoptotic
BNIP3, and downregulated pro-apoptotic BNIP3L and
pro-apoptotic MOAP1 (Figure 1).
Caspases play a central role as executioners in most types
of apoptosis, including activation induced cell death
(AICD). However they have not been discussed during T-BMC Medical Genomics 2008, 1:53 http://www.biomedcentral.com/1755-8794/1/53
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Expression profiles of genes associated with regulation of apoptosis Figure 1
Expression profiles of genes associated with regulation of apoptosis. Genes that were differentially expressed tempo-
rally in T-cell activation of the three (CD3+, CD4+ and CD8+) populations were divided into two groups (A with mostly 
upregulated genes, and B with mostly downregulated genes) according to their distinct expression patterns based on hierarchi-
cal clustering using the Euclidean distance metric. Color denotes degree of differential expression compared to 0 hour (satu-
rated red = 3-fold up-regulation, saturated green = 3-fold down-regulation, black = unchanged, gray = no data available). 
Expression data shown are averages from three independent biological experiments for each T-cell population. The median 
ratio, along with the maximum (for up-regulated genes) or minimum (for down-regulated genes) ratio of stimulated T cells at 
each timepoint (with respect to the expression of 0 hour) is provided (a negative value represents down-regulation). Pro-apop-
totic genes names and descriptions are shown in red, anti-apoptotic genes are shown in green and genes with both pro- and 
anti-apoptosis roles are shown in blue. Genes with unknown functions in apoptosis are shown in black. (C) Schematic view of 
significantly regulated genes of BCL2 family. Green and red connections denote negative and positive regulation of apoptosis, 
respectively, based on information of NCBI website [18]. Regulation of gene transcription in CD3+ T cells, compared to 0 
hour, is denoted by different color (green: downregulation, red: upregulation) at each timepoint in the sequence of 4, 10, 48 
and 96 hours.
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cell activation. Our microarray data show that numerous
caspase genes were differentially expressed. Contrary to
the signalling mechanism whereby CASP9 becomes acti-
vated first, and then in turn activates CASP3 and CASP6
[4], at the transcriptional level, CASP3 was upregulated at
24–96 hours, earlier than CASP9 and CASP6, which were
only upregulated at 96 hours. The flow cytometric assay
specific for the active form of caspase 3 protein (sample
flow cytometry histograms shown in Additional file 2.)
supported the involvement of CASP3 by 48 hours (Figure
2E). CASP8AP2, which is required in CASP8 mediating
apoptosis [27], was downregulated at 4–10 hours and
then upregulated to the same level of resting T cells at 48–
96 hours. CASP1, as well as its adaptor PYCARD [28], and
CASP4 displayed decreased expression throughout, sug-
gesting that CASP1 and CASP4 might play important roles
in the homeostasis of resting T cells, but not in T-cell acti-
vation. Caspase regulatory protein AVEN (reportedly an
inhibitor of CASP9 activation) [29] was upregulated at
10–48 hours, concomitantly with the upregulation of
CASP9 at 96 hours. CFLAR (CASP8 and FADD-like apop-
tosis regulator) was significantly and continuously upreg-
ulated. CFLAR has different roles in T cells at different
stages. It has been reported that CFLAR is induced by res-
timulaiton in activated T cells, inhibiting FAS-mediated
apoptosis [30], while overexpression of CFLAR in naive T
cells decreased T-cell proliferation upon anti-CD3/anti-
CD28 stimulation [31]. The strong transcriptional upreg-
ulation of CFLAR in T-cell activation, not previously
reported, suggests an important role during the process of
primary T-cell activation.
Some heat shock proteins are involved in apoptosis, but
none has been discussed in the context of T-cell activation.
HSPE1 and HSPD1 shared continuously elevated expres-
sion at 4–96 hours. It has been hypothesized that HSPE1
and HSPD1 form a complex with and facilitate the activa-
tion of pro-caspase 3 [32]. Anti-apoptotic interacting heat
shock proteins HSPA9 and HSP90B1 [33,34] were also
upregulated; their role remains unknown in T-cell activa-
tion. Of note, reportedly anti-apoptotic HSPA5 [35], dem-
onstrated distinct transcription patterns in the three
populations: it was upregulated in CD3+ T cells especially
at 48 hours, but overall downregulated in both CD4+ and
CD8+ T cells. HSPA5 has been reported to retain T-cell
antigen receptor alpha chain (TCR-alpha) within the
endoplasmic reticulum [36]. These different expression
patterns among the three T-cell populations indicate that
HSPA5 might be involved in the interaction between
CD4+ and CD8+ T cells in T-cell activation.
The transcriptional kinetics of other significantly regu-
lated, and not-previously reported in T-cell activation
apoptotic genes are also worth discussing briefly. These
include members of the inhibitor of apoptosis protein
(IAP) family, and genes of programmed cell death
(PDCD) proteins. IAPs inhibit apoptosis by interfering
with activation of caspase proteins [37]. The differentially
expressed genes of the IAP family displayed different
expression patterns: BIRC1 and BIRC2 were downregu-
lated, BIRC5 was down-then-upregulated, and BIRC3 was
up-down-upregulated. Of note, pro-apoptotic PDCD5
and AIF1 (PDCD8) were upregulated at 10–96 hours.
Non-caspase executor proteases, such as Granzyme B
(GZMB) and CTSB (cathepsin B), were also significantly
regulated. Besides its function in inducing target cell
apoptosis, intracellular degranulated GZMB has also been
implicated in AICD in TH2 cells [38]. Our microarray data
revealed that GZMB was continuously upregulated with
similar transcription patterns in CD4+ T cell and CD8+ T
cells, suggesting an involvement of GZMB in T-cell activa-
tion. CTSB has been reported to promote T-cell apoptosis
by immune-suppressive anti-T cell agents, mitogen
antithymocyte globulins (ATGs) [39]. Transcription of
CTSB was downregulated first (at 4–48 hours) then upreg-
ulated at 96 hours, thus suggesting a role of CTSB in the
early stage of T-cell proliferation.
The TNF receptor family plays important roles in extrinsi-
cally induced apoptotic pathways. Some TNF receptors
have death domains and are directly involved in apopto-
sis. Transcription of several TNF receptors (TNFRSF6, -8, -
9, -18, -1A, -1B, -10A, -10B, and -25) was differentially
regulated. Of note, TNFRSF6 (FAS), the well-known AICD
receptor, was upregulated at 4–10 hours, but not the other
two components of the death-inducing signalling com-
plex (DISC): FADD and CASP8 [40]. FAS has also been
implicated in multiple pathways including NF-κB, extra-
cellular signal-regulated protein kinase (ERK) 1 and -2,
and p38; however, the function of FAS in early T-cell acti-
vation has not been reported [4]. Contrary to the reported
induction of death-receptors TNFRSF1A and TNFRSF25
(DR3) in T-cell activation [41,42], our microarray data
show that both are downregulated, together with TRADD
(TNFRSF1A-associated death domain protein), their com-
mon adaptor protein. These data suggest that the apopto-
sis pathways mediated by TNFRSF1A/TRADD and
TNFRSF25/TRADD are suppressed upon T-cell activation.
TNFRSF1B was upregulated and more significantly so in
CD8+ T cells. The function of TNFRSF1B in T cells remains
controversial, with both anti-apoptotic and pro-apoptotic
functions reported [43,44]. Furthermore, TNFRSF1B has
not been reported to be T-cell subset (CD4+ or CD8+)
specific. BIRC3 (also known as IAP1), component of the
TNFRSF1B signalling complexes inducing apoptosis [45],
was more significantly upregulated in CD8+ T cells, simi-
larly to TNFRSF1B. This suggests that the TNFRSF1B sig-
nalling might have CD8+ specific functions. A few TNFSF
and TNFRSF related proteins, the function of whichBMC Medical Genomics 2008, 1:53 http://www.biomedcentral.com/1755-8794/1/53
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remain largely unknown, were significantly regulated.
These included FAIM (FAS apoptotic inhibitory mole-
cule), FAF1 (Fas associated factor 1), and SIVA (CD27
(TNFRSF7)-binding protein)), which were downregulated
first and then upregulated; and TNFAIP8, which was
upregulated first and then downregulated.
Numerous TNF receptors and related proteins involved in
NF-κB signalling pathway were significantly regulated in
T-cell activation. TNFRSF8, reportedly able to promote
apoptosis through inducing the activation of NF-κB com-
plex [46], was significantly upregulated at 48–96 hours.
TNFRSF9, reportedly able to promote apoptosis and sup-
press the activation of NF-κB complex [47], was mainly
upregulated. TNFRSF10A (TRAILR1) and TNFRSF10B
(TRAILR2), which can interact with several members of
TRAFs to activate NF-κB complex [48], together with sev-
eral members of the TRAF family (TRAF4, TRAF1, TRAF3,
and TRAF6) were upregulated. A detailed examination of
the transcriptional orchestration of NF-κB signaling path-
way in T-cell activation is presented next.
NF-κB signalling pathway
The transcription factor NF-κB complex, a collection of
several homodimers or heterodimers of Rel proteins (REL,
RELA (p65), RELB, p50 and p52), plays a key role for the
regulation of T-cell activation by mediating the induction
of various genes that control T-cell proliferation, activa-
tion and survival [49]. A wide array of stimuli including
IL1, and TNF as well as TCR stimulation lead to the onset
of cascades that ultimately lead to NF-κB activation [2].
Due to the broad range of the upstream signalings and the
complexity of the dimers, our knowledge of the orches-
trated regulation of NF-κB signalling pathway and activity
of the different NF-κB dimers in T-cell activation is far
from complete. The transcriptional regulation of signifi-
cantly regulated genes associated with the NF-κB signal-
ling pathway is shown in Figure 3A and Figure 4A. NF-κB
family genes (REL, RELA (p65), and RELB) and IκB family
genes (NFKBIA (the inhibitor of RELA), NFKBIE (inhibi-
tor of REL) and NFKB1 (p105, precursor of p50)) shared
similar transcription patterns, an early upregulation at 4–
10 hours was followed by a decrease at 48–96 hours. IKIP
(IKK interacting protein) was significantly upregulated at
48–96 hours (Figure 3A). We also examined the intracel-
lular protein expression of phosphorylated p65, the major
active component of the NF-κB complex. Flow cytometric
analysis (sample flow cytometry histograms shown in
Additional file 2.) demonstrated an increase of the phos-
phorylated p65 at 48–96 hours (Figure 3B). This activa-
tion delay is likely the result of the strong upregulation of
NFKBIA at 4 and 10 hours. It is also possible that p65
might quickly become activated within 4 hours leading to
the transcriptional induction of NFKBIA, one of the target
genes of the NF-κB complex [50]. Of note, not only the
Protein expression profiles of (A) BCL2A (C) BBC3 and (E)  active CASP3 Figure 2
Protein expression profiles of (A) BCL2A (C) BBC3 
and (E) active CASP3. Protein expression kinetics sup-
ports the transcriptional patterns of selected genes demon-
strated by microarray analysis. CD3+ T cells were selected, 
stimulated (with anti-CD3/anti-CD28 antibodies), cultured 
and harvested at the indicated timepoints of culture to ana-
lyze the protein expression by flow cytometric assays. For 
BCL2A and BBC3, data from two independent experiments, 
E4 and E5, are shown; for CASP3, data from three independ-
ent experiments, E1, E4 and E5, are shown. (B), (D) and (F) 
demonstrated the transcriptional patterns of BCL2A1, BBC3 
and CASP3 in all three populations (CD3+, CD4+ and 
CD8+).
-3
0
3
6
CD3+
CD4+
CD8+
0 2 44 87 29 6
E4
E5
0
0
A
E4
E5
BCL2A1
BBC3
96 72 48 24
Timepoint (hours)
4
3
2
1
P
r
o
t
e
i
n
 
e
x
p
r
e
s
s
i
o
n
 
r
a
t
i
o
 
(
v
s
.
 
0
h
) 24
18
12
6
C
0
6
12
18
24
0 2 44 87 29 6
BCL2A1
CD3+
CD4+
CD8+
T
r
a
n
s
c
r
i
p
t
i
o
n
 
e
x
p
r
e
s
s
i
o
n
 
r
a
t
i
o
 
(
v
s
.
 
0
h
)
0
24
18
12
6
09 6 72 48 24
Timepoint (hours)
B
e
x
p
r
e
s
s
i
o
n
 
r
a
t
i
o
 
(
v
s
.
 
0
h
)
o
n
 
e
x
p
r
e
s
s
i
o
n
 
r
a
t
i
o
 
(
v
s
.
 
0
h
)
6
3
0
-3
BBC3 D
0
2
4
6
8
0 2 44 87 29 6
CD3+
CD4+
CD8+
-6
0 2 44 87 29 6
0 2 44 87 29 6
E4
E5
E1
0 2 44 87 29 6
Active CASP3
0
E
09 6 72 48 24
Timepoint (hours)
P
r
o
t
e
i
n
 
e
T
r
a
n
s
c
r
i
p
t
i
o
-6
09 6 72 48 24
Timepoint (hours)
P
r
o
t
e
i
n
 
e
x
p
r
e
s
s
i
o
n
 
r
a
t
i
o
 
(
v
s
.
 
0
h
) 4
3
2
1
0
09 6 72 48 24
Timepoint (hours)
T
r
a
n
s
c
r
i
p
t
i
o
n
 
e
x
p
r
e
s
s
i
o
n
 
r
a
t
i
o
 
(
v
s
.
 
0
h
)
09 6 72 48 24
Timepoint (hours)
Active CASP3 F
8
6
4
2
0BMC Medical Genomics 2008, 1:53 http://www.biomedcentral.com/1755-8794/1/53
Page 7 of 14
(page number not for citation purposes)
transcriptional regulation of RELB (maximum fold
change of 7.4) was more significant than that of RELA
(maximum fold change of 6.5), but also RELB had higher
transcriptional levels than RELA. BCL3, a transcriptional
coactivator of NF-κB homodimer p50/p50 and p52/p52
[51], was upregulated at 4 and 96 hours.
TLR1 (toll-like receptor) and TICAM1 (toll-like receptor
adaptor), which promote activation of the NF-κB complex
[52], showed decreased expression at 48–96 hours, sug-
gesting that this upstream activation cascade of the NF-κB
complex might not be active during early T-cell prolifera-
tion. Also involved in NF-κB complex activity regulation,
members of the TNF receptor super family (TNFRSF6, -8,
-9, -10A, and -10B), their associated proteins (TRAF1, -3, -
4 and -6, EDARADD (ectodysplasin A receptor-associ-
ated)) and TRAF interacting protein (TRAIP) showed
increased expression. TNFRSF-10A, -10B, TRAF1, -3, and -
6 were upregulated at 4–10 hours and TRAIP, which
inhibits the TRAF-mediated NF-κB activation [53], was
upregulated at 48–96 hours. This orchestrated gene
expression regulation suggests that the TRAF-mediated
upstream signalling of NF-κB activation is active at 4–10
hours. Furthermore, the early upregulation of MAP3
Kinases (MAP3K14, MAP3K8, MAP3K7IP2) supports the
early involvement of the TNF receptor pathway since
MAP3 Kinases activate IκB kinases recruited by TRAFs to
the TNF receptor complex [54]. In contrast, TNFRSF1A,
TRADD (TNFRSF1A-associated via death domain) and
TRAF5 were downregulated, suggesting that the reported
TNFRSF1A-TRADD-TRAF2 cascade [55] and TRAF5 medi-
ated cascade [56], regulating the activation of NF-κB com-
plex, might not be active in T-cell activation.
TCR specific signalling protein MALT1 (through the
CARD11-BCL10-MALT1 complex) was recently reported
to be required for optimal NF-κB activation through pro-
teolysis of the NF-κB inhibitor TNFAIP3 [57,58]. However
the transcriptional regulation of MALT1 and TNFAIP3 in
T-cell activation has not been reported. Our microarray
data demonstrated that MALT1 was upregulated at 4 and
96 hours, and TNFAIP3 was upregulated at 4 hours and
downregulated at 10–96 hours. CARD11 and BCL10 were
not identified as significantly regulated, however. CARD9,
the equivalent gene of CARD11 in dendritic cells [59], was
upregulated at 4 and 10 hours, suggesting its involvement
in T-cell activation.
Matsuda et al. identified genes whose transcription can
induce the activation of the NF-κB complex by introduc-
ing cDNA clones of full-length human cDNA libraries to
HEK 293 cells [60]. Our microarray data demonstrated
that several of these genes were significantly regulated
with different transcription patterns (gene names shown
in blue in Figure 3A). Some of these genes were upregu-
lated, such as UBE2N, ECT2, TFG, and FKBP1A; while oth-
Significantly regulated genes in NF-κB signalling pathway Figure 3
Significantly regulated genes in NF-κB signalling 
pathway. (A) Expression profiles of genes involved in NF-
κB signalling pathway. Color denotes degree of differential 
expression compared to 0 hour (saturated red = 3-fold up-
regulation, saturated green = 3-fold down-regulation, black = 
unchanged, gray = no data available). Expression data shown 
are averages from three independent biological experiments 
for each T-cell population. The median ratio, along with the 
maximum (for up-regulated genes) or minimum (for down-
regulated genes) ratio of stimulated T cells at each timepoint 
(with respect to the expression of 0 hour) is provided (a neg-
ative value represents down-regulation). Genes, whose tran-
scription can induce the activation of the NF-κB complex, 
identified in a large scale screening study [60] were shown in 
blue. (B) Protein expression profile of phosphorylated p65 
of NF-κB complex. CD3+ T cells were selected, stimulated 
(with anti-CD3/anti-CD28 antibodies), cultured and har-
vested at the indicated timepoints of culture to analyze the 
protein expression by flow cytometric assays. Data from two 
independent experiments, E4 and E5, are shown. (C) The 
transcriptional pattern of RELA in all three populations 
(CD3+, CD4+ and CD8+).
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Pathway schematic of significantly regulated genes in (A) NF-κB signalling and (B) MAP kinase signalling Figure 4
Pathway schematic of significantly regulated genes in (A) NF-κB signalling and (B) MAP kinase signalling. Mem-
bership was manually determined from the corresponding gene pages in NCBI [18] and references therein. The regulation of 
gene transcription in CD3+ T cells, compared to 0 hour, is denoted by different color (green: downregulation, red: upregula-
tion) at each timepoint in the sequence of 4, 10, 48 and 96 hours.
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ers were downregulated, such as SCOTIN, APOL3 and
FLNA. Two NF-κB inhibitor-like proteins (NFKBIL1 and
NFKBIL2), whose function has not been determined, were
significantly upregulated at 96 hours and 48 hours respec-
tively, suggesting that they are involved in early T-cell pro-
liferation and late T-cell activation, respectively.
Some genes (EGR1, NFKBIA and NFKBIE) had signifi-
cantly different expression patterns in CD4+ and CD8+ T
cells compared to CD3+ T cells. NFKBIA and NFKBIE are
inhibitors of REL proteins, and EGR1 has been reported to
inhibit the activity of RELA [61]. It is possible that the
communication between CD4+ and CD8+ T cells may
affect the activation of the NF-κB complex. Activation of
the NF-κB complex is further supported by the significant
regulation of many target genes, whose transcription is
regulated by NF-κB complex upon anti-CD3/anti-CD28
stimulation (Additional file 1). Interestingly, some of
these target genes showed higher expression in resting T
cells.
MAP kinase signalling
Mitogen-activated protein (MAP) kinases are important
signalling mediators in regulation of apoptosis, including
the anti-apoptotic ERKs, the anti-/pro-apoptotic c-Jun N-
terminal kinases (JNKs), and anti-/pro-apoptotic p38-
MAPKs. Yet the mechanisms as to how these MAP kinases
regulate apoptosis remain controversial [62]. It has been
suggested that the three main mammalian cell MAP
kinase cascades, JNK, p38 and ERK, are essential for T-cell
functions [63,64]. However, the temporal regulation of
these MAP kinase cascades in T-cell activation remains
largely unexplored. Thus, we focused on the significantly
regulated genes involved in MAP kinase signalling path-
way (Figure 4B and Figure 5). A few genes of the RAS fam-
ily and RAS regulating protein were upregulated upon
anti-CD3/anti-CD28 T-cell stimulation, including HRAS
(at 10–48 hours), KRAS (at 4 hours), NRAS (at 4–96
hours) and ADORA2B (at 4–96 hours). HRAS, KRAS and
NRAS have been reported to be activated shortly after TCR
stimulation [65], however the regulation of their expres-
sion (either at the transcriptional or protein level) has not
been reported. ADORA2B reportedly regulates ERK and
p38 MAP kinase cascades in mast cells [66], but its func-
tion in T cells is not known. Contrary to upregulated RAS
genes, several upstream RAS regulating proteins
(RASGRP1, -2, ADRB2, GRAP, ERBB2) showed higher
expression in resting T cells (Figure 5A). The downregula-
tion of RASGRP1 and GRAP does not correlate with their
reportedly positive roles in T-cell receptor signalling
[67,68]. Little is known about RASGRP2, ADRB2, and
ERBB2 in the context of T-cell activation. Contrary to the
reported activation of RAC proteins CDC42 and RAC2
[69,70] in T-cell activation, here we found that their tran-
scription was downregulated.
Several kinases in the MAP kinase signalling pathway were
differentially expressed. A few kinases upstream of the
JNK cascade (MAP4K2 [71], MAP4K1 [72], MAP3K12
[73], MAP4K4 [74], MAP3K2 [75]) were downregulated,
and MBIP (MAP3K12 binding inhibitory protein), which
inhibits the MAP3K12 mediated JNK activation [76], was
upregulated, suggesting that the JNK cascade might not be
active at 4–96 hours. MAPK14 (p38), MAPK3 (ERK1),
MKNK1 (the interacting protein of both p38 and ERK1
[77]) and MAP2K6 (p38 specific MAP kinase kinase [78])
displayed similar regulation patterns: downregulated at
4–10 hours and then upregulated at 48–96 hours. The
flow cytometric assays (sample flow cytometry histograms
shown in Additional file 2.) of phosphorylated p38 and
ERK1 confirmed their transcriptional patterns, namely
that there was no significant increase of phosphorylated
p38 until 24 hours and phosphorylated ERK1 until 48
hours, but large increases after that until 96 hours (Figure
5B and Figure 5D). Kinases involved in positive regulation
of activity of the NF-κB complex, MAP3K14 [79] and
MAP3K8 [80], showed increased expression at 4–10 hours
which is consistent with expression patterns of several
members of NF-κB and IκB family genes (Figure 3A). Two
less examined kinases, MAPK6 and MAPK12, were mainly
upregulated at 4–48 hours and at 10–96 hours respec-
tively, suggesting that they are actively involved in T-cell
activation.
Several MAP kinase regulating proteins were also differen-
tially expressed upon anti-CD3/anti-CD28 activation of T
cells. Members of the dual specificity phosphatase family,
negatively regulating members of the MAP kinase family,
show different expression patterns. DUSP1, able to inacti-
vate ERK1, JNK and p38 [81], was significantly downreg-
ulated throughout. In contrast, DUSP5, specific inhibitor
of ERK1 [82], was strongly upregulated at 4–10 hours and
decreased thereafter in concert with the upregulation of
ERK1 at 48–96 hours at both the transcriptional and pro-
tein level (Figure 5A and Figure 5C). DUSP8, of which lit-
tle is known, was significantly upregulated at 4 hours and
then downregulated at 48–96 hours, which is opposite to
the transcriptional pattern of MAPK14 and MAPK3. Some
transcription factors regulated by MAP kinase pathway
were downregulated, and most intensely so were FOS and
JUN. FOS and JUN proteins are the main components of
the transcription factor complex AP-1. AP-1 has been
reported to be quickly activated in response to T-cell acti-
vation [83], which is contradictory to the significant
downregulation of FOS and JUN. The temporal activity of
AP-1 in T-cell activation is not known. Thus, we examined
the DNA-binding activity of AP-1, which rapidly increased
within 4 hours and then rapidly decreased (Figure 5D). It
is possible that FOS and JUN were immediately and tran-
siently regulated upon anti-CD3/anti-CD8 stimulation,BMC Medical Genomics 2008, 1:53 http://www.biomedcentral.com/1755-8794/1/53
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Significantly regulated genes involved in MAP kinase signalling Figure 5
Significantly regulated genes involved in MAP kinase signalling. (A) Expression profiles of genes that belong to the list 
of MAP kinase pathways. Color denotes degree of differential expression compared to 0 hour (saturated red = 3-fold up-regu-
lation, saturated green = 3-fold down-regulation, black = unchanged, gray = no data available). Expression data shown are aver-
ages from three independent biological experiments for each T-cell population. The median ratio, along with the maximum (for 
up-regulated genes) or minimum (for down-regulated genes) ratio of stimulated T cells at each timepoint (with respect to the 
expression of 0 hour) is provided (a negative value represents down-regulation). (B) Protein expression profiles of phosphor-
ylated p38 and of (D) phosphorylated ERK1 agree with the late transcription upregulation of MAPK8 and MAPK3. CD3+ T 
cells were selected, stimulated (with anti-CD3/anti-CD28 antibodies), cultured and harvested at the indicated timepoints of 
culture to analyse the protein expression by flow cytometric assays. Data from two independent experiments, E4 and E5, are 
shown. (F) DNA-binding activity profile of transcription factor AP-1 captured the immediate and transient activation of AP-1 
in T-cell activation. CD3+ T cells were selected, stimulated (with anti-CD3/anti-CD28 antibodies), cultured and harvested at 
the indicated timepoints of culture. Data from three independent experiments, E1, E4 and E5, are shown. (C), (E), (G) and 
(H) demonstrated the transcriptional patterns of MAPK14 (p38), MAPK3 (ERK1), FOS and JUN (the two major components if 
AP-1) in all three populations (CD3+, CD4+ and CD8+).
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and that their upregulation was not captured by our first
timepoint following T-cell activation.
Discussion
In this work, we sought to improve our understanding of
regulation of apoptosis in T-cell activation. We
approached this problem by analysing global, temporal
microarray data from ex vivo CD3+, CD4+ and CD8+ T-
cell cultures, and leveraging Gene Ontology associations
and prior knowledge. This approach extended our knowl-
edge base in three ways: we presented detailed kinetic
gene expression information on genes with previously
hypothesized or presumed important roles in apoptosis;
we identified a new set of genes not previously associated
with T-cell activation; and, we integrated and connected
the previous knowledge with temporal transcription pro-
files to build a more comprehensive picture of regulation
of apoptosis in T-cell activation. Gene expression data
were further explored by examining protein expression
(active form/phosphorylated form) and functional activ-
ity levels as a first assessment of their functional role.
Genome-scale transcription profiling provides the oppor-
tunity to more holistically evaluate the regulation of a
group of genes, of the same family, or with analogous
functions, or associated in specific pathways. Composed
of several members, the BCL2 family proteins are key
players in regulation of apoptosis. BCL2, BAX, BAK have
been reported to play important roles in apoptosis post
activation in T cells [4]. Knockout of pro-apoptotic BBC3
and PMAIP1 decreased DNA damage-induced apoptosis
in mice fibroblasts, but only loss of BBC3 protected lym-
phocytes from cell death [84]. However, the function and
transcriptional regulation of most of the BCL2 family
members and their regulatory proteins remain unex-
plored in T-cell activation. Our data suggest the distinct
stages that BCL2 family members are involved in the proc-
ess of T-cell activation, thus providing directions for future
studies. For instance, validated by protein abundance
assays (Figure 2A and 2B), the functions of continuously
upregulated BCL2A1 and dynamically regulated BBC3
deserve further studies in T-cell activation. The synchro-
nized early transcriptional upregulation of MCL1 and its
inhibitory interacting proteins PMAIP1 [24] and BMF [85]
imply their involvement in T-cell activation quickly upon
TCR ligation.
In typical apoptosis signalling, CASP9 is activated first,
which leads to activation of downstream effectors CASP3,
and CASP6. Here, CASP3 was upregulated (at both the
transcriptional and protein levels) by 48 hours, compared
to the upregulation of CASP9 only at 96 hours. These find-
ings suggest that active CASP3 protein might have a differ-
ent role in T-cell activation and thus its activity might be
regulated by other proteins, such as HSPE1 and HSPD1
(Figure 1A), rather than CASP9. Surprisingly, the well-
known AICD receptor, TNFRSF6 (FAS), was upregulated
at 4–10 hours, suggesting the involvement of FAS imme-
diately upon T-cell activation.
Our data show that numerous significantly regulated
genes associated with apoptosis are involved in NF-κB sig-
nalling pathway and MAP kinase signalling pathway. Sup-
ported by the increase of phosphorylated p65 at 48–96
hours (Figure 3B), the simultaneous upregulation of NF-
κB family genes (REL, RELA, and RELB) and IκB family
genes (NFKBIA, NFKBIE and NFKB1) at 48–96 hours (Fig-
ure 3A) suggests that multiple versions of the NF-κB dim-
mer complex are active during this time period in our
experiments. Lack of early detection of phosphorylated
p65 that multiple versions of the NF-κB dimmer complex
are active during this time period in our experiments
could be the result of the strong upregulation of NFKBIA
at 4–10 hours. It is also possible that p65 might immedi-
ately and transiently become activated, and then quickly
deactivated within 4 hours, our first timepoint. Of note,
IKIP (IκB kinase interacting protein) was significantly
upregulated at 48–96 hours (Figure 3A). To date, the func-
tion of IKIP remains unknown. Its transcriptional kinetics
suggests that it might have a positive role in NF-κB activity
regulation.
Validated by the increase of phosphorylated p38 and
ERK1 at 24–96 hours and 48–96 hours, respectively, as
measured by flow cytometry assays (Figure 5B and Figure
5C), the similar transcriptional patterns of MAPK14
(p38), MAPK3 (ERK1), MKNK1 (the interacting protein
of both MAPK14 and MAPK3 [77]) and MAP2K6 (p38
specific MAP kinase kinase [78]) (downregulated at 4–10
hours and then upregulated at 48–96 hours) suggest that
cascades of p38 and ERK1, but not JNK, are synergistically
activated during late T-cell activation and early prolifera-
tion. Activity of transcription factor AP-1, mostly regu-
lated by JNK and p38 cascades [86], increased
immediately, but only transiently, upon anti-CD3/anti-
CD28 stimulation, suggesting a potentially rapid but tran-
sient activation of JNK and p38 cascades in T-cell activa-
tion. Significantly, there was no activity increase of AP-1 at
48–96 hours, in contrast to the increase of phosphor-
ylated p65. It has been suggested that MAP kinases have
different roles in CD4+ and CD8+ T cells [87]. However
most of the significant regulated genes in MAP kinase sig-
nalling pathway shared similar expression patterns
between the CD4+ and CD8+ subsets. It is possible that
the MAP kinase signalling pathway is regulated similarly
between the two subsets in the context of T-cell activation.
It is also possible that the MAP kinases might function dif-
ferently due to regulation at protein level.BMC Medical Genomics 2008, 1:53 http://www.biomedcentral.com/1755-8794/1/53
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T-cell activation using bead-conjugated-anti-CD3/anti-
CD28 antibodies is an established state-of-the art method
[88] for both fundamental studies, such as gene-expres-
sion profiling [6,89], as well as for clinical immuno-
therapy applications [90]. It provides both the stimulatory
and costimulatory signals [91,92] and the physical con-
tact, in place of APCs [93], and as such it is assumed to
mimic the in vivo situation. Consistent with that assump-
tion, and for well-established genes partaking in the T-cell
activation process, our data are consistent with the large
body of literature (a good fraction of which comes from
in vivo studies) on T-cell activation.
Conclusion
Our study captured novel temporal patterns of previously
known but many novel, in the context of T-cell activation,
genes ontologically classified under the term 'regulation
of apoptosis'. These patterns were reproducibly and
robustly identified as donor independent. Comprehen-
sively integrating previous knowledge, we identified novel
significant genes associated with regulation of apoptosis
in T cells, as well as with NF-κB and MAPK signalling
pathways. This study improves our understanding of the
biology and the underlying regulation mechanisms of
apoptosis in T-cell activation in the natural CD3+ popula-
tion, as well as in the CD4+ and CD8+ subsets.
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